EP 2086933 A2 20090812 - NOVEL INDOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Title (en)
NOVEL INDOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Title (de)
NEUARTIGE INDOLDERIVATE, HERSTELLUNGSVERFAHREN DAFÜR UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN DAMIT
Title (fr)
NOUVEAUX DERIVES INDOLIQUES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
Publication
Application
Priority
- FR 2007001707 W 20071017
- FR 0609114 A 20061018
Abstract (en)
[origin: FR2907452A1] Indole derivatives (I), their enantiomers, diastereomers and their acid/base addition salts are new. Indole derivatives of formula (I), their enantiomers, diastereomers and their acid/base addition salts are new. R 11-6C alkyl, 3-8C cycloalkyl or 3-8C cycloalkyl-1-6C alkyl, preferably methyl; R 21-6C alkyl, preferably methyl, ethyl or propyl; and n : 1-6, preferably 2. An independent claim is included for the preparation of (I). [Image] ACTIVITY : Hypnotic; Tranquilizer; Antidepressant; Cardiovascular-Gen; Gastrointestinal-Gen; Neuroleptic; Anorectic; Anticonvulsant; Antidiabetic; Antiparkinsonian; Nootropic; Antimigraine; Neuroprotective; Endocrine-Gen; Contraceptive; Immunomodulator; Cytostatic. MECHANISM OF ACTION : Melatonin receptor binder. The affinity of (I) to bind with melatonin receptors MT1 and MT2 was tested using 2-[ 1> 2> 5>I]-iodomelatonin as reference radioligand. The results showed that (I) exhibited an inhibition constant value of less than 1 mu M.
IPC 8 full level
A61K 31/404 (2006.01); A61P 3/04 (2006.01); A61P 15/00 (2006.01); A61P 25/00 (2006.01); A61P 35/00 (2006.01); C07D 209/42 (2006.01)
CPC (source: EP KR US)
A61K 31/404 (2013.01 - KR); A61K 31/4045 (2013.01 - KR); A61P 1/00 (2017.12 - EP); A61P 3/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 9/00 (2017.12 - EP); A61P 9/10 (2017.12 - EP); A61P 15/00 (2017.12 - EP); A61P 15/18 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/04 (2017.12 - EP); A61P 25/10 (2017.12 - EP); A61P 25/16 (2017.12 - EP); A61P 25/18 (2017.12 - EP); A61P 25/20 (2017.12 - EP); A61P 25/22 (2017.12 - EP); A61P 25/24 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 35/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 209/42 (2013.01 - EP KR US)
Citation (search report)
See references of WO 2008049996A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
Designated extension state (EPC)
AL BA HR MK RS
DOCDB simple family (publication)
FR 2907452 A1 20080425; FR 2907452 B1 20081212; AU 2007310769 A1 20080502; AU 2007310769 B2 20110811; BR PI0717453 A2 20131224; CA 2666497 A1 20080502; CN 101522617 A 20090902; EA 200900480 A1 20091030; EP 2086933 A2 20090812; GE P20115192 B 20110325; JP 2010506889 A 20100304; KR 20090089323 A 20090821; MA 30795 B1 20091001; MX 2009004007 A 20090427; NO 20091794 L 20090506; UA 91646 C2 20100810; US 2010063128 A1 20100311; US 8003682 B2 20110823; WO 2008049996 A2 20080502; WO 2008049996 A3 20080619; ZA 200902413 B 20100728
DOCDB simple family (application)
FR 0609114 A 20061018; AU 2007310769 A 20071017; BR PI0717453 A 20071017; CA 2666497 A 20071017; CN 200780036361 A 20071017; EA 200900480 A 20071017; EP 07858467 A 20071017; FR 2007001707 W 20071017; GE AP2007011252 A 20071017; JP 2009532843 A 20071017; KR 20097010134 A 20071017; MA 31791 A 20090416; MX 2009004007 A 20071017; NO 20091794 A 20090506; UA A200904633 A 20071017; US 31178707 A 20071017; ZA 200902413 A 20071017